Therapeutic Benefit of Hsp90 Inhibition in Pulmonary Fibrosis
Abstract
IPF is a fatal fibrotic lung disease associated with aberrant activation of fibroblasts and progressive fibrosis. The pirfenidone therapy for IPF has been shown to slow the rate of decline in lung function but do not halt ongoing fibrosis. This application will test whether inhibition of HSP90 activity, coupled with antifibrotic therapy of pirfenidone, will attenuate WT1-driven fibroblast activation. The proposed studies will provide robust, highly novel observations to rapidly pursue the long-term goal: Translational exploration of the molecular mechanisms by which HSP90 activity positively regulates IPF pathogenesis in order to devise novel preventive and therapeutic strategies for IPF.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1124290
Entities
People
- Satish K Madala